Siga Technologies Inc (NASDAQ: SIGA)

SIGA Technologies, Inc., a commercial-stage pharmaceutical company (NASDAQ: SIGA), operates in the development and commercialization of medical countermeasures for biological threats. The company's main business activities involve the creation and sale of antiviral drugs to combat smallpox and monkeypox. SIGA's operations span across the United States, with a significant portion of its revenue generated through contracts with the U.S. Department of Defense (DoD) and other organizations, as well as through the sale of its lead product, TPOXX, to the U.S. government and international governments.

TPOXX is SIGA's primary product, an oral antiviral drug approved by the US Food and Drug Administration (FDA) for the treatment of smallpox and monkeypox. Manufactured by W.R. Grace and Company, TPOXX is distributed by Packaging Coordinators, LLC (PCI) and sold to the US government and international governments. The European Commission's DG HERA (Health Emergency Preparedness and Response Authority) joint procurement mechanism is among its customers.

In addition to TPOXX, SIGA is developing an intravenous (IV) formulation of the drug, intended for patients requiring intravenous administration. Several contract manufacturing organizations (CMOs), including Roquette America, Inc., Patheon Manufacturing Services LLC, and PCI, are partnered with SIGA for the manufacturing and packaging of the IV formulation.

SIGA's research and development contracts with the DoD and other organizations provide funding for the development and improvement of TPOXX. These activities include clinical trials and manufacturing scale-up. As a leading developer and manufacturer of medical countermeasures for biological threats, SIGA's competitive advantages include its FDA-approved TPOXX product, partnerships with CMOs, and research and development contracts with the DoD and other organizations.

SIGA's primary customers are government agencies, including the US Department of Health and Human Services (HHS) and the DoD, as well as international governments and organizations. The company's products are used to treat a range of biological threats, including smallpox, monkeypox, and other orthopoxviruses.